


Betamethasone Acetate

Site: Valladolid, Spain

CAS Number: 987-24-6

Marketed Formulation: Injection - long acting




Betamethasone Base

Site: Valladolid, Spain

CAS Number: 378-44-9

Marketed Formulation: Topical, oral liquid, tab, delayed release tab




Betamethasone Benzoate

Site: Valladolid, Spain

CAS Number: 22298-29-9

Marketed Formulation: Topical



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.


Betamethasone Butyrate Propionate

Site: Valladolid, Spain

CAS Number: 2/1/34

Marketed Formulation: Ointment, lotion and cream

Regulatory Submission: Japan DMF




Betamethasone-17,21-Dipropionate

Site: Valladolid, Spain

CAS Number: 5593-20-4

Marketed Formulation: Topical cream, lotion, ointment

Regulatory Submission: CEP, China, Japan DMF, US DMF




Betamethasone-17,21- Dipropionate Sterile

Site: Valladolid, Spain

CAS Number: 5593-20-4

Marketed Formulation: Injection - long acting

Regulatory Submission: EU DMF



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.


Betamethasone-21-Phosphate Disodium Salt

Site: Valladolid, Spain

CAS Number: 151-73-5

Marketed Formulation: Injection - long acting

Regulatory Submission: CEP, China, Japan DMF, Russia, US DMF




Betamethasone Valerate Acetate

Site: Valladolid, Spain

CAS Number: 5919-89-1

Marketed Formulation: Topical




Betamethasone-17-Valerate

Site: Valladolid, Spain

CAS Number: 2152-44-55

Marketed Formulation: Topical

Regulatory Submission: CEP, Japan DMF, Russia



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.